Table 2.
Percentages of phenotypes observed after microinjection of small GTPase proteins into human melanoma cells
| Cells | Treatment | Time, min | F‡ | L | SF |
|---|---|---|---|---|---|
| M2 | Control | 60 | 4.8 ± 2.0 | 5.7 ± 1.2 | 10.3 ± 0.3 |
| V23RalA | 90 | 5.8 ± 3.9 | 0.0 ± 0.0 | 0.0 ± 0.0 | |
| V23RalA + N17Cdc42 | 60 | 0.0 ± 0.0 | N.D. | N.D. | |
| RhoA | 180 | 3.6 ± 1.8 | 7.8 ± 4.3 | 52.7 ± 6.4 | |
| Rac | 150 | 6.5 ± 4.1 | 31.2 ± 5.1 | 1.8 ± 1.8 | |
| V12Cdc42 | 70 | 8.1 ± 4.6 | 2.7 ± 1.3 | 1.3 ± 1.3 | |
| A7 | Control | 60 | 11.8 ± 2.5 | 9.0 ± 1.2 | 2.0 ± 0.3 |
| V23RalA | 90 | 52.7 ± 8.2 | 9.0 ± 4.3 | 0.0 ± 0.0 | |
| V23RalA + N17Cdc42 | 60 | 67.2 ± 4.5 | N.D. | N.D. | |
| RhoA | 180 | 5.9 ± 0.8 | 4.8 ± 2.1 | 64.6 ± 7.8 | |
| Rac | 150 | 9.1 ± 1.7 | 40.7 ± 9.4 | 0.0 ± 0.0 | |
| V12Cdc42 | 70 | 48.8 ± 6.1 | 3.2 ± 1.1 | 0.0 ± 0.0 | |
| M2 (δCT112) | |||||
| Control | 90 | 60.0 ± 7.0 | 4.0 ± 1.0 | 0.0 ± 0.0 | |
| V23RalA | 90 | 57.9 ± 4.9 | 0.0 ± 0.0 | 0.0 ± 0.0 |
Experimental conditions are described and the data are expressed as in Table 1. The concentration of microinjected RhoA and Racl are RhoA (1.0 mg/ml) and Racl (1.8 mg/ml), respectively. F, filopodia; L, lamellipodia, SF, stress fibers; N.D., not determined.